SAN DIEGO, June 23, 2023 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (“Calidi”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, today announced the commitment of $25 million in Series B funding led by Jackson Investment Group (“JIG”), who has funded an initial…Read More
MILOSI Calidi Biotherapeutics Announces Commitment of 25 Million in Series B Funding to Advance
